The superior sensitivity and specificity of PSMA-PET compared to conventional imaging techniques have prompted its inclusion in primary staging protocols for high-risk PCa, as recommended by the latest EAU guidelines. The gene discussed is FOLH1; the disease is posterior cortical atrophy.